The meal test
Ipamorelin: show me the meal.
The early chemistry impressed me. The trial about eating after surgery tells a less comfortable story.
The meal that outgrew the molecule
I arrived expecting an argument about growth hormone. Instead, the human efficacy paper put a meal at the centre of the story. Ipamorelin was tested for postoperative ileus, the temporary slowing of the bowel after surgery; the question was whether people could tolerate food sooner.
In the published trial of 114 adults after bowel resection, the median time to a first tolerated meal was 25.3 hours with ipamorelin and 32.6 hours with placebo. The primary endpoint was missed, with p=0.15. A smaller number on the page did not establish a treatment benefit.
That ordinary endpoint is why this file interests me. A medicine has to do something useful in a person's life, and the study gave ipamorelin a concrete opportunity to show it. The trial concerned bowel recovery. Sleep, fat loss and recovery from training remain untested human outcomes, and the clinical disappointment lends my skepticism about those broader promises some weight.
Selective was a real achievement
Before that trial, there was a genuinely interesting molecule. Ipamorelin is a synthetic chain of five amino acids that activates the ghrelin receptor and prompts the pituitary to release growth hormone. In the 1998 experiments in rat cells, rats and swine, it released growth hormone without the ACTH and cortisol spillover seen with older growth-hormone-releasing peptides, even at more than 200 times its growth-hormone ED50.
ED50 is the amount that produces half the maximum measured response. The swine figure was 2.3 nmol/kg, compared with 3.9 nmol/kg for GHRP-6. I admire this precise piece of engineering: a narrower hormonal effect, rather than an indiscriminate push. Calling it selective is justified by these acute animal experiments. Calling it a proven wellness medicine asks the word to carry far more.
The human volunteer study later recorded a growth-hormone pulse peaking around 40 minutes and an approximately 2-hour terminal half-life after intravenous administration. That is a useful pharmacological result. Better sleep is still an unanswered clinical question.
The missing card in the stack
The name now often appears beside CJC-1295. There is a sensible reason: the peptides act at different receptors, and studies of related growth-hormone-releasing peptides with GHRH have shown more-than-additive hormone release. Yet the hexarelin synergy experiment used hexarelin, while the long-acting CJC-1295 study studied CJC-1295 on its own. Neither tested the popular pair.
I object to signing off a clinical file for CJC-1295 and ipamorelin on the strength of that collection. The orthopaedic review describes a muscle-tension finding in mice. The combination has no controlled human outcome trial demonstrating a wellness benefit.
The stack file traces those borrowed findings. Ipamorelin research follows the molecule through the published record, and ipamorelin vs sermorelin compares two quite different routes through drug development.